Bone mass and long-term monophasic oral contraceptive treatment in young women

Franco Polatti; Francesca Perotti; Nadia Filippa; Davide Gallina; Rossella E. Nappi

doi:10.1016/0010-7824(95)00036-A

Bone mass and long-term monophasic oral contraceptive treatment in young women

Franco Polatti, Francesca Perotti, Nadia Filippa, Davide Gallina, Rossella E. Nappi

IRCCS Fondazione Policlinico San Matteo

Research output: Contribution to journal › Article › peer-review

Abstract

A prospective study has been designed to investigate bone metabolism in young women taking an oral monophasic contraceptive formulation (ethinylestradiol 20 μg + desogestrel 0.150 mg) over 5 years. Healthy women (n = 200) between 19 and 22 years of age were divided into two groups. Group A received oral contraception, Group B did not receive any treatment. All the subjects underwent a bone mass density (BMD) evaluation at spinal level L2-L4 with Dexa (Norland XR-26) and a measurement of the serum alkaline phosphatase levels and urinary excretion of OH-proline at baseline and every 12 months over 5 years. Our results demonstrated that Group A did not show any significant BMD change after 5 years of oral contraceptive treatment, while Group B demonstrated a significant increase (p

Original language	English
Pages (from-to)	221-224
Number of pages	4
Journal	Contraception
Volume	51
Issue number	4
DOIs	https://doi.org/10.1016/0010-7824(95)00036-A
Publication status	Published - 1995

Keywords

alkaline phosphatase
bone mass density
monophasic contraceptive
urinary excretion

ASJC Scopus subject areas

Obstetrics and Gynaecology
Reproductive Medicine
Medicine(all)

Access to Document

10.1016/0010-7824(95)00036-A

Cite this

@article{9f793f85897c4b8d9f5655a8dca28fea,

title = "Bone mass and long-term monophasic oral contraceptive treatment in young women",

abstract = "A prospective study has been designed to investigate bone metabolism in young women taking an oral monophasic contraceptive formulation (ethinylestradiol 20 μg + desogestrel 0.150 mg) over 5 years. Healthy women (n = 200) between 19 and 22 years of age were divided into two groups. Group A received oral contraception, Group B did not receive any treatment. All the subjects underwent a bone mass density (BMD) evaluation at spinal level L2-L4 with Dexa (Norland XR-26) and a measurement of the serum alkaline phosphatase levels and urinary excretion of OH-proline at baseline and every 12 months over 5 years. Our results demonstrated that Group A did not show any significant BMD change after 5 years of oral contraceptive treatment, while Group B demonstrated a significant increase (p ",

keywords = "alkaline phosphatase, bone mass density, monophasic contraceptive, urinary excretion",

author = "Franco Polatti and Francesca Perotti and Nadia Filippa and Davide Gallina and Nappi, {Rossella E.}",

year = "1995",

doi = "10.1016/0010-7824(95)00036-A",

language = "English",

volume = "51",

pages = "221--224",

journal = "Contraception",

issn = "0010-7824",

publisher = "Elsevier USA",

number = "4",

}

TY - JOUR

T1 - Bone mass and long-term monophasic oral contraceptive treatment in young women

AU - Polatti, Franco

AU - Perotti, Francesca

AU - Filippa, Nadia

AU - Gallina, Davide

AU - Nappi, Rossella E.

PY - 1995

Y1 - 1995

N2 - A prospective study has been designed to investigate bone metabolism in young women taking an oral monophasic contraceptive formulation (ethinylestradiol 20 μg + desogestrel 0.150 mg) over 5 years. Healthy women (n = 200) between 19 and 22 years of age were divided into two groups. Group A received oral contraception, Group B did not receive any treatment. All the subjects underwent a bone mass density (BMD) evaluation at spinal level L2-L4 with Dexa (Norland XR-26) and a measurement of the serum alkaline phosphatase levels and urinary excretion of OH-proline at baseline and every 12 months over 5 years. Our results demonstrated that Group A did not show any significant BMD change after 5 years of oral contraceptive treatment, while Group B demonstrated a significant increase (p

AB - A prospective study has been designed to investigate bone metabolism in young women taking an oral monophasic contraceptive formulation (ethinylestradiol 20 μg + desogestrel 0.150 mg) over 5 years. Healthy women (n = 200) between 19 and 22 years of age were divided into two groups. Group A received oral contraception, Group B did not receive any treatment. All the subjects underwent a bone mass density (BMD) evaluation at spinal level L2-L4 with Dexa (Norland XR-26) and a measurement of the serum alkaline phosphatase levels and urinary excretion of OH-proline at baseline and every 12 months over 5 years. Our results demonstrated that Group A did not show any significant BMD change after 5 years of oral contraceptive treatment, while Group B demonstrated a significant increase (p

KW - alkaline phosphatase

KW - bone mass density

KW - monophasic contraceptive

KW - urinary excretion

UR - http://www.scopus.com/inward/record.url?scp=0028916930&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028916930&partnerID=8YFLogxK

U2 - 10.1016/0010-7824(95)00036-A

DO - 10.1016/0010-7824(95)00036-A

M3 - Article

C2 - 7796586

AN - SCOPUS:0028916930

VL - 51

SP - 221

EP - 224

JO - Contraception

JF - Contraception

SN - 0010-7824

IS - 4

ER -

Bone mass and long-term monophasic oral contraceptive treatment in young women

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this